Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly EBITDA Margin came in at 290.47% in Q2 2026, down 14185.0% on a YoY basis from N/an in Q2 2025, and up 20.75% quarter-over-quarter from 366.51% in Q1 2026.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has reported EBITDA Margin for 7 consecutive years, with 290.47% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 14185.0% year-over-year to 290.47%; the trailing twelve-month figure through Jun 2026 stood at 259.86% (down 11816.0% YoY), and the FY2025 full-year result was 185.29%, up 6125.0% from the prior year.
- EBITDA Margin rose to 290.47% in Q2 2026 per DNA's latest filing, from 366.51% in the prior quarter.
- Across five years, EBITDA Margin topped out at 61.99% in Q3 2024 and bottomed at 986.38% in Q3 2022.
- Historically, EBITDA Margin has averaged 321.18% across 5 years, with a median of 251.81% in 2024.
- The widest YoY moves for EBITDA Margin: up 89966 bps in 2022, down 95202 bps in 2022.
- Over 5 years, EBITDA Margin stood at 234.89% in 2022, then jumped by 69 bps to 73.27% in 2023, then sank by 222 bps to 236.29% in 2024, then grew by 10 bps to 211.86% in 2025, then slumped by 37 bps to 290.47% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 290.47%, 366.51%, and 211.86% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 42.77 Bn | 40.69 Bn | 1.44 Bn | 11.58% |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 21.68% |
| 3 | Charles River Laboratories International | 13.37 Bn | 13.18 Bn | 452.07 Mn | 11.94% |
| 4 | Icon | 12.49 Bn | 11.56 Bn | 479.29 Mn | 15.86% |
| 5 | Fortrea Holdings | 1.58 Bn | 1.42 Bn | 139.20 Mn | 2.18% |
| 6 | Evotec SE | 642.83 Mn | 216.96 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 422.55 Mn | 338.02 Mn | 18.44 Mn | -290.47% |
| 8 | Champions Oncology | 69.16 Mn | 69.16 Mn | 7.03 Mn | -3.77% |
| 9 | MindWalk Holdings | 59.83 Mn | 51.55 Mn | 1.82 Mn | -77.57% |
| 10 | VivoSim Labs | 1.45 Mn | 1.45 Mn | - | -15,327.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -290.47% |
| Mar 31, 2026 | -366.51% |
| Dec 31, 2025 | -211.86% |
| Sep 30, 2025 | -231.78% |
| Jun 30, 2025 | -148.63% |
| Mar 31, 2025 | -211.80% |
| Dec 31, 2024 | -236.29% |
| Sep 30, 2024 | -61.99% |
| Jun 30, 2024 | -396.66% |
| Mar 31, 2024 | -469.12% |
| Dec 31, 2023 | -73.27% |
| Sep 30, 2023 | -516.68% |
| Jun 30, 2023 | -228.57% |
| Mar 31, 2023 | -267.34% |
| Dec 31, 2022 | -234.89% |
| Sep 30, 2022 | -986.38% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |